Brief: Eagle Pharmaceuticals Submits Response To Complete Response Letter From FDA For Vasopressin
17/06/2021 12:03
June 17 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS SUBMITS RESPONSE TO COMPLETE
RESPONSE
LETTER FROM FDA FOR VASOPRESSIN
* EAGLE PHARMACEUTICALS - ANTICIPATE HAVING FINAL APPROVAL
IN
TIME TO LAUNCH VASOPRESSIN THIS YEAR
Source text for Eikon: ID:nBw3sHF80a
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq